**Seq&Treat — End-to-end targeted sequencing solutions for drug-resistant TB detection — Questionnaire for analytical validation (Phase 1) and clinical evaluation (Phase 2)**

**Name of organization:** \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Contact details:**

Contact Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Phone: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Information required to determine inclusion in Phase 1 analytical validation (Please select)**

|  |  |  |
| --- | --- | --- |
| Do you currently have a design-locked, end-to-end targeted sequencing solution1[[1]](#footnote-1) with the potential to meet published target product profile requirements[[2]](#footnote-2) for detecting XDR-TB and PZA-resistance? | Yes  No |  |
| If not, by when: | |  |
| Is your end-to-end solution currently ready for internal testing with a panel of reference samples to be supplied by FIND? | Yes  No |  |
| If not, by when: | |  |
| Are the components of the end-to-end solution currently manufactured under GMP / ISO:13485? | Yes  No |  |
| If not, by when: | |  |

**Please provide additional product specifications below:**

|  |
| --- |
| **DNA extraction** |
| Please provide details of your DNA extraction methodology, including but not limited to, starting material requirements, equipment, reagents, batching, etc. |
|  |
| **Library preparation** |
| Please provide details of your library preparation process, including but not limited to, input volume requirements, equipment, reagents, batching, quality control, etc. |
|  |
| **Sequencing** |
| Please provide details of your sequencing method, including but not limited to, sequencing platform, instrument, batching, run time, etc. |
|  |
| **Data analysis** |
| Please provide details of the integrated data analysis component of your solution, including but not limited to level of automation, reporting, hardware and software requirements, run time, etc. |
|  |
| **Additional information** |
| Please use this space to provide any additional information |

All the information in this form will be treated as confidential and will be used for internal purposes only. Please send your completed forms or any questions to [info@finddx.org](mailto:info@finddx.org), putting **Seq&Treat TB NGS** in the subject line.

1. An end-to-end solution will include all of the equipment, reagents and software necessary for implementing the entire targeted sequencing workflow, including handling of processed sputum samples, DNA extraction, library preparation, sequencing, and data analysis/interpretation for clinical result reporting. [↑](#footnote-ref-1)
2. <https://apps.who.int/iris/bitstream/handle/10665/274443/WHO-CDS-TB-2018.19-eng.pdf> [↑](#footnote-ref-2)